drugset
Drugs / Folfox4 plus recombinant human endostatin (Endostar)
last change Oct 2010 re-read 3 minutes ago

Folfox4 plus recombinant human endostatin (Endostar)

Developed for
colorectal cancer
Investigated by
Simcere Pharmaceutical Co., Ltd · The Affiliated Changzhou Tumor Hospital of Suzhou University

Trials 1

today NCT00813137 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00813137 Oct 2008 → Oct 2010 colorectal cancer Simcere Pharmaceutical Co., Ltd Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Folfox4 plus recombinant human endostatin (Endostar) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813137 ↗
Route Intravenous “CF 200mg/m2 iv drip D1,2,15,16” NCT00813137 ↗